Table 3.

Pharmacokinetics (PK) parameters of pembrolizumab (human anti‐PD‐1) administrated subcutaneously in Wistar Han rats using crystalline formulation and monoclonal antibody (mAb) laden alginate hydrogel particle formulation

Formulation	Crystalline formulation	mAb‐laden ALG particles formulation
C max/Dose	0.005	0.005
T max [h]	48	48
AUC/Dose	1.4	1.4
Vz‐F [mL kg−1]	94	123
CL [mL h−1 kg−1]	0.7	0.7
Mean residence time [h]	171	174
AUCinf [h*µg mL−1]	62 222	57 495

Vz/F: apparent volume of distribution. AUC: area under the curve. CL: apparent total body clearance.